Lyell Immunopharma
Founded Year
2018Stage
IPO | IPOTotal Raised
$851MDate of IPO
6/17/2021Market Cap
1.34BStock Price
5.46Research containing Lyell Immunopharma
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Lyell Immunopharma in 3 CB Insights research briefs, most recently on May 13, 2020.
Apr 16, 2020
Did Covid-19 Impact Startup Financing Activity?Expert Collections containing Lyell Immunopharma
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Lyell Immunopharma is included in 3 Expert Collections, including Biopharma Tech.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Cancer
3,605 items
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Lyell Immunopharma Patents
Lyell Immunopharma has filed 5 patents.
The 3 most popular patent topics include:
- Clusters of differentiation
- Immune system
- Immunology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/19/2021 | Transcription factors, Clusters of differentiation, Tyrosine kinase receptors, Olfactory receptors, Immune system | Application |
Application Date | 3/19/2021 |
|---|---|
Grant Date | |
Title | |
Related Topics | Transcription factors, Clusters of differentiation, Tyrosine kinase receptors, Olfactory receptors, Immune system |
Status | Application |
Latest Lyell Immunopharma News
Jun 7, 2022
San Francisco, California, UNITED STATES SOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14 at 10:40am PT. A live webcast of the fireside chat can be accessed through the investor relations section of the Company's website at www.lyell.com. Following the live presentation, a replay of the webcast will be available on the Company's website for 90 days following the presentation date. About Lyell Immunopharma, Inc. Lyell is a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors. The Company is advancing a pipeline of therapies designed to address what it believes are the primary barriers that limit consistent, reliable and curative responses to adoptive T-cell therapy: T-cell exhaustion and lack of durable stemness, which includes the ability to proliferate, persist and self-renew, as well as generate differentiated effector cell progenies to provide durable anti-tumor functionality. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable and potentially curative clinical outcomes. Lyell is based in South San Francisco, California and Seattle and Bothell, Washington. To learn more, please visit www.lyell.com. Contact:
Lyell Immunopharma Web Traffic
Lyell Immunopharma Rank
When was Lyell Immunopharma founded?
Lyell Immunopharma was founded in 2018.
Where is Lyell Immunopharma's headquarters?
Lyell Immunopharma's headquarters is located at 400 E Jamie Ct, South San Francisco.
What is Lyell Immunopharma's latest funding round?
Lyell Immunopharma's latest funding round is IPO.
How much did Lyell Immunopharma raise?
Lyell Immunopharma raised a total of $851M.
Who are the investors of Lyell Immunopharma?
Investors of Lyell Immunopharma include ARCH Venture Partners, Altitude Life Science Ventures, Foresite Capital and 8VC.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.